Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H17N3O5S.H2O |
Molecular Weight | 381.404 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C3=CC=C(O)C=C3)C2=O)C(O)=O
InChI
InChIKey=NBFNMSULHIODTC-CYJZLJNKSA-N
InChI=1S/C16H17N3O5S.H2O/c1-7-6-25-15-11(14(22)19(15)12(7)16(23)24)18-13(21)10(17)8-2-4-9(20)5-3-8;/h2-5,10-11,15,20H,6,17H2,1H3,(H,18,21)(H,23,24);1H2/t10-,11-,15-;/m1./s1
Molecular Formula | C16H17N3O5S |
Molecular Weight | 363.388 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Cefadroxil is a new semisynthetic cephalosporin with a broad antibacterial spectrum and a high chemotherapeutic potential when administered orally. Many studies have established the efficacy of the administration of once- or twice-daily cefadroxil in the management of infections in the respiratory tract, urinary tract, skin and soft tissues, and bones and joints.
CNS Activity
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
The importance of Bi-Digital O-Ring Test in the treatment of multiple hepatic abscesses: a case history. | 2003 |
|
Non-hospital antimicrobial usage and resistance in community-acquired Escherichia coli urinary tract infection. | 2003 Dec |
|
Enhanced intestinal absorption of drugs by activation of peptide transporter PEPT1 using proton-releasing polymer. | 2003 Nov |
|
Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study. | 2003 Oct |
|
Comparison of azithromycin and cefadroxil for the treatment of uncomplicated skin and skin structure infections. | 2003 Sep |
|
Antimicrobial resistance in Escherichia coli in urine samples from children and adults: a 12 year analysis. | 2004 Apr |
|
Meta-analysis of cephalosporin versus penicillin treatment of group A streptococcal tonsillopharyngitis in children. | 2004 Apr |
|
Synthesis, characterization and electronic spectra of cefadroxil complexes of d-block elements. | 2004 Aug |
|
Comparison of trimethoprim-sulfamethoxazole, cephadroxil and cefprozil as prophylaxis for recurrent urinary tract infections in children. | 2004 Feb |
|
Mechanisms of cefadroxil uptake in the choroid plexus: studies in wild-type and PEPT2 knockout mice. | 2004 Feb |
|
Penicillin acylase-catalyzed synthesis of beta-lactam antibiotics in highly condensed aqueous systems: beneficial impact of kinetic substrate supersaturation. | 2004 Feb 5 |
|
Thiolated chitosans: development and in vitro evaluation of a mucoadhesive, permeation enhancing oral drug delivery system. | 2004 Jan 8 |
|
Comparative bioavailability of two cefadroxil products using serum and urine data in healthy human volunteers. | 2004 Jul |
|
Minimum inhibitory concentrations for 25 selected antimicrobial agents against Dichelobacter nodosus and Fusobacterium strains isolated from footrot in sheep of Portugal and Spain. | 2004 Jun |
|
Physician behaviour for antimicrobial prescribing for paediatric upper respiratory tract infections: a survey in general practice in Trinidad, West Indies. | 2004 Jun 14 |
|
Direct visualization of peptide uptake activity in the central nervous system of the rat. | 2004 Jun 24 |
|
Molecularly imprinted solid phase extraction-pulsed elution-mass spectrometry for determination of cephalexin and alpha-aminocephalosporin antibiotics in human serum. | 2004 Nov 15 |
|
Antimicrobial susceptibility of skin-colonizing S. aureus strains in children with atopic dermatitis. | 2004 Oct |
|
The use of a monolithic column to improve the simultaneous determination of four cephalosporin antibiotics in pharmaceuticals and body fluids by HPLC after solid phase extraction--a comparison with a conventional reversed-phase silica-based column. | 2004 Sep 25 |
|
Staphylococcal skin infections in children: rational drug therapy recommendations. | 2005 |
|
PEPT2 (Slc15a2)-mediated unidirectional transport of cefadroxil from cerebrospinal fluid into choroid plexus. | 2005 Dec |
|
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. | 2005 Jan |
|
Heterogeneity of the IgE response to allergenic determinants of cefaclor in serum samples from patients with cefaclor-induced anaphylaxis. | 2005 Jun |
|
Bactericidal activity of oral beta-lactam antibiotics in plasma and urine versus isogenic Escherichia coli strains producing broad- and extended-spectrum beta-lactamases. | 2005 Jun |
|
Presumed pituitary abscess without infectious source treated successfully with antibiotics alone. | 2005 Sep |
|
Functional expression of the peptide transporter PEPT2 in the mammalian enteric nervous system. | 2005 Sep 12 |
|
A sensitive assay of amoxicillin in mouse serum and broncho-alveolar lavage fluid by liquid-liquid extraction and reversed-phase HPLC. | 2005 Sep 15 |
|
Quantitative structure/activity relationship modelling of pharmacokinetic properties using genetic algorithm-combined partial least squares method. | 2006 |
|
Urinary bactericidal activity of oral antibiotics against common urinary tract pathogens in an ex vivo model. | 2006 |
|
Determination of cefadroxil by sequential injection with spectrophotometric detector. | 2006 Apr |
|
Positive effect of natural and negatively charged cyclodextrins on the stabilization of penicillins towards beta-lactamase degradation due to inclusion and external guest-host association. An NMR and MS study. | 2006 Apr 7 |
|
Medication use for pediatric upper respiratory tract infections. | 2006 Aug |
|
European Surveillance of Antimicrobial Consumption (ESAC): outpatient cephalosporin use in Europe. | 2006 Aug |
|
Choroid plexus epithelial monolayers--a cell culture model from porcine brain. | 2006 Dec 21 |
|
Cephalosporins can be prescribed safely for penicillin-allergic patients. | 2006 Feb |
|
Molecular interactions between dipeptides, drugs and the human intestinal H+ -oligopeptide cotransporter hPEPT1. | 2006 Jul 1 |
|
Chemiluminescence flow-injection analysis of beta-lactam antibiotics using the luminol-permanganate reaction. | 2006 Jul-Aug |
|
Chiral separation of cefadroxil by capillary electrochromatography. | 2006 Jun 16 |
|
Development of a Health-Related Quality of Life Questionnaire (HRQL) for patients with Extremity Soft Tissue Infections (ESTI). | 2006 Oct 11 |
|
Generalizability in two clinical trials of Lyme disease. | 2006 Oct 17 |
|
Treatment of lichen sclerosus with antibiotics. | 2006 Sep |
|
Flow injection chemiluminescence determination of cefadroxil using potassium permanganate and formaldehyde system. | 2006 Sep 18 |
|
Species distribution and properties of staphylococci from canine dermatitis. | 2007 Feb |
|
Impact of genetic knockout of PEPT2 on cefadroxil pharmacokinetics, renal tubular reabsorption, and brain penetration in mice. | 2007 Jul |
|
Idiopathic granulomatous mastitis masquerading as carcinoma of the breast: a case report and review of the literature. | 2007 Jul 27 |
|
Demonstration of functional dipeptide transport with expression of PEPT2 in guinea pig cardiomyocytes. | 2007 Mar |
|
Human oral drugs absorption is correlated to their in vitro uptake by brush border membrane vesicles. | 2007 May 4 |
|
Fluorescence studies of the dehydration of cefadroxil monohydrate. | 2007 Oct |
|
In vitro activity of cefadroxil, cephalexin, cefatrizine and cefpirome in presence of essential and trace elements. | 2007 Oct |
|
A comparative study of capillary zone electrophoresis and pH-potentiometry for determination of dissociation constants. | 2007 Sep 3 |
Sample Use Guides
Cefadroxil tablets are acid-stable and may be administered orally without regard to meals. Administration with food may be helpful in diminishing potential gastrointestinal complaints occasionally associated with oral cephalosporin therapy. Adults Urinary Tract Infections For uncomplicated lower urinary tract infections (i.e., cystitis) the usual dosage is 1 or 2 g per day in a single (q.d.) or divided doses (b.i.d.). For all other urinary tract infections the usual dosage is 2 g per day in divided doses (b.i.d.). Skin and Skin Structure Infections For skin and skin structure infections the usual dosage is 1 g per day in single (q.d.) or divided doses (b.i.d.). Pharyngitis and Tonsillitis Treatment of group A beta-hemolytic streptococcal pharyngitis and tonsillitis – 1 g per day in single (q.d.) or divided doses (b.i.d.) for 10 days. Children For urinary tract infections, the recommended daily dosage for children is 30 mg/kg/day in divided doses every 12 hours. For pharyngitis, tonsillitis, and impetigo, the recommended daily dosage for children is 30 mg/kg/day in a single dose or in equally divided doses every 12 hours. For other skin and skin structure infections, the recommended daily dosage is 30 mg/kg/day in equally divided doses every 12 hours. In the treatment of beta-hemolytic streptococcal infections, a therapeutic dosage of Cefadroxil tablets should be administered for at least 10 days.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Oct 21 19:50:46 UTC 2019
by
admin
on
Mon Oct 21 19:50:46 UTC 2019
|
Record UNII |
280111G160
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C357
Created by
admin on Mon Oct 21 19:50:46 UTC 2019 , Edited by admin on Mon Oct 21 19:50:46 UTC 2019
|
||
|
WHO-VATC |
QJ01DB05
Created by
admin on Mon Oct 21 19:50:46 UTC 2019 , Edited by admin on Mon Oct 21 19:50:46 UTC 2019
|
||
|
CFR |
21 CFR 520.314
Created by
admin on Mon Oct 21 19:50:46 UTC 2019 , Edited by admin on Mon Oct 21 19:50:46 UTC 2019
|
||
|
NDF-RT |
N0000175488
Created by
admin on Mon Oct 21 19:50:46 UTC 2019 , Edited by admin on Mon Oct 21 19:50:46 UTC 2019
|
||
|
LIVERTOX |
159
Created by
admin on Mon Oct 21 19:50:46 UTC 2019 , Edited by admin on Mon Oct 21 19:50:46 UTC 2019
|
||
|
WHO-ATC |
J01DB05
Created by
admin on Mon Oct 21 19:50:46 UTC 2019 , Edited by admin on Mon Oct 21 19:50:46 UTC 2019
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
204175
Created by
admin on Mon Oct 21 19:50:46 UTC 2019 , Edited by admin on Mon Oct 21 19:50:46 UTC 2019
|
PRIMARY | |||
|
C28912
Created by
admin on Mon Oct 21 19:50:46 UTC 2019 , Edited by admin on Mon Oct 21 19:50:46 UTC 2019
|
PRIMARY | |||
|
D002434
Created by
admin on Mon Oct 21 19:50:46 UTC 2019 , Edited by admin on Mon Oct 21 19:50:46 UTC 2019
|
PRIMARY | |||
|
M3185
Created by
admin on Mon Oct 21 19:50:46 UTC 2019 , Edited by admin on Mon Oct 21 19:50:46 UTC 2019
|
PRIMARY | Merck Index | ||
|
407888
Created by
admin on Mon Oct 21 19:50:46 UTC 2019 , Edited by admin on Mon Oct 21 19:50:46 UTC 2019
|
ALTERNATIVE | |||
|
Cefadroxil
Created by
admin on Mon Oct 21 19:50:46 UTC 2019 , Edited by admin on Mon Oct 21 19:50:46 UTC 2019
|
PRIMARY | |||
|
CHEMBL1644
Created by
admin on Mon Oct 21 19:50:46 UTC 2019 , Edited by admin on Mon Oct 21 19:50:46 UTC 2019
|
PRIMARY | |||
|
66592-87-8
Created by
admin on Mon Oct 21 19:50:46 UTC 2019 , Edited by admin on Mon Oct 21 19:50:46 UTC 2019
|
PRIMARY | |||
|
SUB13272MIG
Created by
admin on Mon Oct 21 19:50:46 UTC 2019 , Edited by admin on Mon Oct 21 19:50:46 UTC 2019
|
PRIMARY | |||
|
DB01140
Created by
admin on Mon Oct 21 19:50:46 UTC 2019 , Edited by admin on Mon Oct 21 19:50:46 UTC 2019
|
PRIMARY | |||
|
47964
Created by
admin on Mon Oct 21 19:50:46 UTC 2019 , Edited by admin on Mon Oct 21 19:50:46 UTC 2019
|
PRIMARY | |||
|
2177
Created by
admin on Mon Oct 21 19:50:46 UTC 2019 , Edited by admin on Mon Oct 21 19:50:46 UTC 2019
|
ALTERNATIVE | |||
|
4831
Created by
admin on Mon Oct 21 19:50:46 UTC 2019 , Edited by admin on Mon Oct 21 19:50:46 UTC 2019
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR | |||
|
PARENT -> SALT/SOLVATE | |||
|
BASIS OF STRENGTH->SUBSTANCE |
calculated on the anhydrous basis
ASSAY (HPLC)
USP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
EP
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||